MOORESTOWN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation digital software solutions and novel, proprietary medication decision support tools, announced today that its Enhanced MTM offerings have been expanded in Medicare Part D Region 25 to address the pervasive challenge of opioid prescribing.
This new scope of work, which began during fourth quarter 2017, relates to engaging and educating physicians about the dangers of prescribing opioids to patients who simultaneously are taking other medications that may interfere with how the body processes these drug combinations. Multi-drug interactions relating to opioids can give rise to serious adverse drug events – even death. These types of multi-drug interactions typically are not identified using traditional drug-interaction database services.
TRHC’s Chairman and Chief Executive Officer, Calvin H. Knowlton, PhD notes that, “Our Medication Risk Mitigation software identifies concomitant medications that compete with opioids for similar metabolic pathways resulting in phenoconversion, which impedes the opioid medication from becoming activated. We find that such multi-drug competition leads to higher opioid dosing, increased medical spend, diminished pain relief, and unintended opioid misuse.”
As part of the education and intervention process, TRHC risk stratifies members using MedWise Advisor® to identify those at high risk for multi-drug interactions in combination with opiates. TRHC’s simultaneous, multi-drug, Medication Risk Mitigation Matrix®, identifies these interactions and is being used to mitigate the dangers of opioids and the risk of adverse drug events. TRHC then collaborates with physicians to reduce patients’ medication risk.
About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable health care organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TabulaRasa.com.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date including statements regarding risk stratification under the new scope of work. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2017, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
Bob East or Asher Dewhurst